Topical skin compositions for treating rosacea and skin redness
A method of topically applying to skin a composition comprising a water soluble Phoenix dactylifera seed extract, an essential oil from the leaves of tea tree, an aqueous Myrothamnus flabellifolia leaf and stem extract, and a saccharide isomerate comprising an exopolysaccharide of Vibrio alginolyticus is disclosed.
1. A method of treating a fine line or wrinkle on the skin under a human's eye and/or moisturizing the skin under a human's eye, the method comprising topically applying to the fine line or wrinkle on the skin under the human's eye a composition comprising:
a Melaleuca alternifolia leaf extract;
a Myrothamnus flabellifolia leaf and stem extract;
a saccharide isomerate;
caprylic/capric triglyceride;
glycerin;
xanthan gum;
hyaluronic acid; and
sodium hyaluronate;
wherein the fine line or wrinkle on the skin under the human's eye is reduced and/or the moisture of the skin under the human's eye is increased.
2. The method of claim 1 , wherein the composition reduces oxidation in the skin of the human.
3. The method of claim 1 , wherein the composition is an emulsion.
4. The method of claim 3 , wherein the emulsion is an oil-in-water emulsion.
5. The method of claim 1 , wherein the composition is a cream or lotion.
6. The method of claim 1 , wherein the composition is a gel.
7. The method of claim 1 , wherein the composition is applied to dry skin under the human's eye, and the composition moisturizes the dry skin under the human's eye.
8. The method of claim 1 , wherein the Melaleuca alternifolia leaf extract comprises an essential oil.
9. The method of claim 1 , wherein the Myrothamnus flabellifolia leaf and stem extract reduces tumor necrosis factor alpha (TNF-α) production and/or inhibits nitric oxide synthase in the skin of the human.
10. The method of claim 1 , wherein the Myrothamnus flabellifolia leaf and stem extract is an aqueous extract.
11. The method of claim 1 , wherein the saccharide isomerate reduces tumor necrosis factor alpha (TNF-α) production and/or inhibits nitric oxide synthase in the skin of the human.
12. The method of claim 1 , wherein the saccharide isomerate comprises an exopolysaccharide of Vibrio alginolyticus.
13. The method of claim 1 , wherein the saccharide isomerate is an aqueous extract of Vibrio alginolyticus.
14. The method of claim 1 , wherein the composition comprises:
0.0001 wt. % to 10 wt. % of the Melaleuca alternifolia leaf extract;
0.0001 wt. % to 10 wt. % of the Myrothamnus flabellifolia leaf and stem extract; and
0.0001 wt. % to 10 wt. % of the saccharide isomerate.
15. The method of claim 1 , wherein the composition comprises at least 50 wt. % water.
16. The method of claim 1 , wherein the composition further comprises a moisturizing agent.
17. The method of claim 1 , wherein the composition further comprises an emulsifier or surfactant.
18. The method of claim 1 , wherein the composition further comprises a ultraviolet light absorption or reflection agent.
19. The method of claim 1 , wherein the composition further comprises:
ascorbic acid;
hydrogenated vegetable oil; and
citric acid.